[18F]PT2385

[18F]PT2385 is a radiolabeled analog of PT2385, a first-in-class small molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α). The [18F] label enables its use as a positron emission tomography (PET) imaging agent to noninvasively assess HIF-2α expression in tumors. This investigational tracer is primarily used in research settings to correlate PET signal with HIF-2α levels determined by immunohistochemistry on tumor tissue. Its main application is in clear cell renal cell carcinoma (ccRCC) and von Hippel-Lindau disease–associated tumors, where HIF-2α plays a key role in pathogenesis. The parent compound, PT2385, was developed by Peloton Therapeutics and validated the therapeutic targeting of HIF-2α; however, [18F]PT2385 itself is not used therapeutically but as an imaging biomarker for target engagement and tumor characterization[6][8].